Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Start of new week recap

<< Previous

Bullboard Posts

Next >>

Comment by Peladawnon Mar 25, 2024 7:21pm

127 Views

Post# 35951833

RE:RE:RE:Start of new week recap

It would also make sense for beginning to roll out sales, once accelerated approval is granted, and the innevetible, subsequent buyout is announced, of thousands of doses to oncology specialists worldwide, and their long-suffering desperate patients who have been waiting for what seem like an eternity to finally be given some real hope.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023